Pancreatic cancer is known for its dismal prognosis despite efforts to improve therapeutic outcome. Recently, cancer nanomedicine, application of nanotechnology to cancer diagnosis and treatment, has gained interest for treatment of pancreatic cancer. The enhanced permeability and retention (EPR) effect that promotes selective accumulation of nanometer-sized molecules within tumors is the theoretical rationale of treatment. However, it is clear that EPR may be insufficient in pancreatic cancer as a result of stromal barriers within the tumor microenvironment (TME).
| INTRODUCTION
Pancreatic cancer has a dismal prognosis despite intensive research over the last several decades. 1 A recent development in treatment is approval of albumin-bound nab-paclitaxel in combination with gemcitabine. This prolongs median survival from 6.7 months (for gemcitabine alone) to 8.5 months. 2 The basic assumption behind nab-paclitaxel is the EPR effect, first proposed in 1986. 3 The EPR hypothesis suggests that tumor neovasculature is immature with underdeveloped lymphatic drainage. This leads to increased leakage of macromolecules from blood vessels (enhanced permeability) and accumulation of leaked macromolecules (enhanced retention).
The EPR effect is the theoretical basis of cancer nanomedicine 4 and its application to diagnosis and/or treatment. However, nanomedicine has yet to reach its full potential. It is becoming increasingly clear that a major hurdle is the existence of a heterogeneous TME 5, 6 in which there exists complex tumor-stromal crosstalk. 7, 8 We therefore aim to provide an overview of the TME and its importance to nanomedicine efficacy in pancreatic cancer. Importantly, we will refer to the biological and physical obstacles that the TME poses to nanomedicine penetration of the tumor as "stromal barriers". We also look at preclinical models of pancreatic cancer and stress the importance of developing clinically relevant models sufficiently recapitulating the characteristics of the TME to promote and accelerate studies on stromal barriers.
| STROMAL BARRIERS TO DRUG DELIVERY WITHIN THE TME IN PANCREATIC CAN CE R
The TME consists of various stromal cell types, 9 and these prevent penetration of nanotherapeutic agents into tumors, thus limiting efficacy. 10 We have previously shown, in a murine BxPC-3 xenograft model of pancreatic cancer, that pharmacological inhibition of TGF-b signaling reduced pericyte coverage and increased intratumoral accumulation of nanotherapeutic agent. This improved efficacy 11, 12 : extending the known role of pericytes in physiological vessel stabilization 13 Fibrosis is thus considered a target in improving drug delivery in pancreatic cancer. 25 However, the way in which fibrotic elements F I G U R E 1 Pancreatic cancer microenvironment. The tumor microenvironment (TME) consists of numerous cell types and extracellular matrix, which collectively affect drug delivery. Pancreatic cancer is notably characterized by fibrosis separating cancer cells from blood vessels. The dotted arrow shows the path that an i.v. given nanoparticle must travel to reach cancer cells and achieve its effects block drug delivery is unclear: it may involve physical obstruction as a result of increased ECM deposition, 24, 26, 27 decreased stromal vessel density, 18, 28 and vessel compression and collapse 22, 23 ( Figure 3 ).
| PRECLINICAL IN VIVO MODELS OF PANCREATIC CAN CE R
The presence of stromal barriers within the TME of pancreatic cancer that limit therapeutic efficacy underscores the need for preclinical models that recapitulate the essential components of the TME.
Here, and in the following section, we describe current models and the steps being taken towards development of new models. This topic has recently also been reviewed elsewhere. 29, 30 The current way of demonstrating efficacy of a particular formulation of nanomedicine is in vivo, usually with mice. Murine pancreatic cancer models can be generally divided into cell-line-based xenograft models, GEMM, and PDX models ( For the present, in vitro 3D tissue studies cannot fully replace in vivo studies. However, they will complement in vivo studies when molecular scale analysis is required and high spatiotemporal resolution may be cumbersome or challenging. They may also help interpret the complex crosstalk within the TME.
| GAPS IN OUR UNDE RSTAN DIN G OF STROMAL BARRIERS: FUTURE DIRECTIONS
Here, we discuss major gaps in our understanding of stromal barriers within TME, and examine how to fill these. The long-term safety and efficacy of nanomedicine is also an urgent issue. For example, nanotherapeutic formulations often use an outer coating of PEG to increase biocompatibility, but PEGylated nanoparticles are more rapidly cleared after repeated injections: a process known as ABC. 67, 68 The ABC phenomenon is immunological -caused by generation of IgM antibodies-and may be clinically problematic in multiple dose treatment. 69 Furthermore, research on cobalt-chromium nanoparticles indicates possible DNA damage propagated across cellular barriers. 70, 71 Therefore, immunogenicity and mutagenicity of nanoparticles, the mechanisms by which they develop, and their biological/clinical consequences for the patient, are all topics that require further study.
Finally, in addition to passive targeting through the EPR effect, the development of active targeting by specific markers within TME for intratumoral accumulation of nanotherapeutics also requires study. 72, 73 A number of candidate targets for pancreatic cancer is under consideration and has been reviewed elsewhere. 74 Furthermore, uptake and intracellular behavior of nanoparticles by individual cells must also be tailored to prevent premature degradation and to facilitate optimal therapeutic effect (a concept known as "subcellular targeting"). 75, 76 However, as with passive targeting by EPR, stromal barriers within TME will likely hinder passage of actively targeted nanotherapeutics. This is especially the case following antibody conjugation for active targeting, which further increases the size of nanotherapeutic formulation. Matsumura recently proposed the CAST strategy to circumvent this difficulty. Using antibodies, it first targets extracellular components, such as collagen IV, insoluble fibrin, and tissue factor, within stroma to make a scaffold from which conjugated low-molecular cytotoxic agents can be released and diffuse freely. 27 
| CONCLUSIONS
The existence of stromal barriers within TME which limit therapeutic efficacy of nanomedicine is now clearly established. However, how these barriers develop and how they hinder therapy is far from clear.
Both increased knowledge of the complex crosstalk within TME, and preclinical models that accurately show the complexity of TME, in vivo and in vitro, are needed to advance research and treatment of pancreatic cancer.
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